| Multiple Sclerosis

Ampyra vs Rayos

Side-by-side clinical, coverage, and cost comparison for multiple sclerosis.
Deep comparison between: Ampyra vs Rayos with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.
Safety signalsRayos has a higher rate of injection site reactions vs Ampyra based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Rayos but not Ampyra, including UnitedHealthcare
Sign up to reveal the full AI analysis
Ampyra
Rayos
At A Glance
Oral
Twice daily
Potassium channel blocker
Oral
Daily
Corticosteroid
Indications
  • Multiple Sclerosis
  • Dermatitis, Atopic
  • Allergic rhinitis (disorder)
  • Serum Sickness
  • Dermatitis Herpetiformis
  • Contact Dermatitis
  • Exfoliative dermatitis
  • Mycosis Fungoides
  • Pemphigus
  • Erythema Multiforme
  • Congenital Adrenal Hyperplasia
  • Hypercalcemia
  • thyroiditis; nonsuppurative
  • Adrenal gland hypofunction
  • Crohn Disease
  • Ulcerative Colitis
  • Autoimmune hemolytic anemia
  • Anemia, Diamond-Blackfan
  • Immune thrombocytopenic purpura
  • Pure Red-Cell Aplasia
  • Acute leukemia
  • Lymphoma, Non-Hodgkin
  • Multiple Sclerosis
  • Cerebral Edema
  • Ophthalmia, Sympathetic
  • Uveitis
  • Chronic Obstructive Airway Disease
  • Aspergillosis, Allergic Bronchopulmonary
  • Aspiration pneumonitis
  • Asthma
  • Tuberculosis
  • Extrinsic allergic alveolitis
  • Bronchiolitis Obliterans Organizing Pneumonia
  • Idiopathic eosinophilic pneumonitis
  • Idiopathic Pulmonary Fibrosis
  • Pneumonia, Lipid
  • Sarcoidosis
  • Nephrotic Syndrome
  • Primary gout
  • Ankylosing spondylitis
  • Dermatomyositis
  • Polymyalgia Rheumatica
  • Arthritis, Psoriatic
  • Polychondritis, Relapsing
  • Rheumatoid Arthritis
  • Sjogren's Syndrome
  • Lupus Erythematosus, Systemic
  • Vasculitis
  • Trichinellosis
  • Tuberculosis, Meningeal
Dosing
Multiple Sclerosis 10 mg tablet twice daily approximately 12 hours apart; do not exceed 10 mg twice daily; swallow tablets whole; may be taken with or without food.
All indications Initial dose 5-60 mg once daily with food; RAYOS releases active substance approximately 4 hours after intake. Titrate to lowest effective maintenance dose; withdraw gradually after long-term or high-dose therapy.
Contraindications
  • History of seizure
  • Moderate or severe renal impairment (CrCl <=50 mL/min)
  • History of hypersensitivity to AMPYRA or 4-aminopyridine, including anaphylaxis
  • Known hypersensitivity to prednisone or any excipient
Adverse Reactions
Most common (>=2%) Urinary tract infection, insomnia, dizziness, headache, nausea, asthenia, back pain, balance disorder, multiple sclerosis relapse, paresthesia, nasopharyngitis, constipation, dyspepsia, pharyngolaryngeal pain
Serious Seizures, anaphylaxis
Postmarketing Vomiting, vertigo
Most common Fluid retention, altered glucose tolerance, elevated blood pressure, behavioral and mood changes, increased appetite and weight gain
Serious Anaphylaxis, cardiac arrest, circulatory collapse, congestive heart failure, myocardial rupture, pulmonary edema, peptic ulcer with perforation and hemorrhage, osteonecrosis, pathologic fracture, adrenocortical insufficiency, convulsions, increased intracranial pressure
Postmarketing No new safety concerns identified beyond those established for immediate-release prednisone
Pharmacology
Dalfampridine is a broad spectrum potassium channel blocker that increases conduction of action potentials in demyelinated axons through inhibition of potassium channels; the mechanism by which it improves walking in MS has not been fully elucidated.
Prednisone is a synthetic corticosteroid with potent anti-inflammatory and immunosuppressive properties that suppresses inflammatory processes (edema, capillary dilatation, leukocyte migration), modifies immune responses, and produces metabolic effects including promotion of gluconeogenesis, protein catabolism, and altered calcium and electrolyte balance.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Ampyra
  • Covered on 5 commercial plans
  • PA (10/12) · Step Therapy (1/12) · Qty limit (9/12)
View full coverage details ›
Rayos
  • Covered on 5 commercial plans
  • PA (6/12) · Step Therapy (1/12) · Qty limit (0/12)
View full coverage details ›
UnitedHealthcare
Ampyra
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (1/8)
View full coverage details ›
Rayos
  • Covered on 4 commercial plans
  • PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
View full coverage details ›
Humana
Ampyra
  • Covered on 0 commercial plans
  • PA (3/3) · Step Therapy (1/3) · Qty limit (3/3)
View full coverage details ›
Rayos
  • Covered on 0 commercial plans
  • PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
View full coverage details ›
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Multiple Sclerosis - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
No savings programs available for Rayos.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
  • Verify eligibility with the payer.
  • Pull the right PA forms directly from the payer.
  • Submit, track & send live updates to your dashboard.
Utilize patient records to autofill forms with our AI in seconds.
Free to start · HIPAA compliant
Next Steps for Your Patient
AmpyraView full Ampyra profile
RayosView full Rayos profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.